Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization

• Published in: Clinical ophthalmology (Auckland, N.Z.) Vol. 3; no. default; pp. 129 - 131
• Main Authors: Ladas, Ioannis D, Moschos, Marilita M, Papakostas, Thanos D, Kotsolis, Athanasios I, Georgalas, Ilias, Apostolopoulos, Michail
• Format: Journal Article
• Language: English
• Published: New Zealand Taylor & Francis Ltd 01.01.2009; Dove Press; Dove Medical Press
• Subjects: age-related macular degeneration; bevacizumab; Case Report; Immunotherapy; Monoclonal antibodies; Ophthalmology; skin rash; skin rash; bevacizumab; age-related macular degeneration
• ISSN: 1177-5467; 1177-5483; 1177-5483
• DOI: 10.2147/OPTH.S4625

The purpose of this observational case report is to describe a case of skin rash after intravitreal use of bevacizumab. A 50-year-old man with choroidal neovascularization in the right eye due to age-related macular degeneration was treated with three intravitreal injections of bevacizumab. Twelve days after the first injection, the patient developed a maculopapular rash on his forehead and on both temporal regions around his eyes. The rash disappeared eight days after treatment with topical corticosteroids. A skin rash with the same distribution reappeared 14 days after the second and 10 days after the third injection. Similarly, it disappeared five and seven days after the use of the same treatment. The follow-up period was 15 months after the third injection. During the follow-up period the rash did not reappear. This case report may initiate further investigation of similar cases to support this observation, as there are a lack of reports of skin rash after intravitreal administration of bevacizumab.